Recent developments include topline Phase 2b results for bezisterim in Parkinson's disease, completion of enrollment in the Phase 2 Long COVID trial, and ongoing Phase 3 protocol finalization for BIV201 in liver cirrhosis-related ascites.

• In August 2026, BioVie announced topline results from the Phase 2b SUNRISE-PD trial showing bezisterim met its primary pharmacodynamic endpoint with significant reduction in neuroinflammatory biomarkers and improvements in motor and non-motor clinical endpoints in early-stage Parkinson's disease patients [S1].
• The Phase 2 ADDRESS-LC trial for bezisterim in Long COVID neurological symptoms completed enrollment in May 2026, with topline results anticipated in late summer 2026 [S1].
• BioVie is finalizing the Phase 3 protocol design for BIV201, focusing on a composite primary endpoint of complications and disease progression in patients with cirrhosis and ascites who have recently recovered from acute kidney injury [S1].
• Phase 2 data for BIV201 showed a significant reduction in ascites fluid volume compared to standard of care, with sustained effects post-treatment [S1].
• The company disclosed risks related to potential dilution from future equity offerings and milestone-based share issuances tied to drug candidates [S2].

BioVie has demonstrated clinical proof-of-concept for bezisterim in Parkinson's disease with statistically significant biomarker and clinical improvements in a Phase 2b trial. The ongoing Phase 2 trial in Long COVID and prior Alzheimer's disease trials suggest potential for multiple indications. The BIV201 program benefits from FDA Fast Track and Orphan Drug designations and positive Phase 2 data showing reductions in ascites fluid, addressing a significant unmet need. The company's novel liquid terlipressin formulation with patent protection and room temperature stability may offer commercial advantages. These factors collectively support the company's potential to advance its pipeline and address large patient populations with limited current treatment options.

BioVie is a clinical-stage company with no approved products and a history of net losses, including a $22 million loss in fiscal 2026. Its Alzheimer's Phase 3 trial was underpowered due to protocol deviations, limiting efficacy conclusions. Clinical development carries inherent risks including trial failures, regulatory delays, and safety concerns. The company faces dilution risks from future equity offerings and milestone-based share issuances. The competitive landscape for neurological and liver disease therapies is challenging, and the company depends on successful clinical development and regulatory approvals to generate revenue. Financial resources may be constrained given current cash levels and ongoing losses.

BioVie's moat is based on its proprietary drug candidates targeting significant unmet medical needs in neurological disorders and liver disease. Its lead compound bezisterim has a novel mechanism targeting neuroinflammation and insulin resistance, supported by clinical trial data and patents. The company also holds patents on novel liquid formulations of terlipressin (BIV201) for liver cirrhosis-related ascites, with regulatory designations such as FDA Fast Track and Orphan Drug status enhancing development incentives. The combination of clinical-stage assets, intellectual property protection across multiple jurisdictions, and regulatory designations provides barriers to entry and potential competitive advantages in its target markets.

• Clinical Development Risk: BioVie's drug candidates are in clinical stages with inherent risks of trial failure, delays, or inability to demonstrate safety and efficacy required for regulatory approval.
• Regulatory Risk: The company depends on FDA approvals and regulatory designations; deviations or issues in clinical trials may lead to delays or non-approval.
• Financial Risk and Dilution: BioVie reported a net loss of $22.07 million for fiscal 2026 and holds $8.98 million in cash. Future capital raises and milestone-based share issuances may dilute existing shareholders.
• Operational Risk: The company experienced significant protocol deviations in its Alzheimer's Phase 3 trial leading to patient exclusions and underpowered results, highlighting operational challenges in clinical trial management.

• BioVie Inc. is a clinical-stage company developing drug therapies for neurological/neurodegenerative disorders and advanced liver disease [S1].
• The company acquired NeurMedix's assets including NE3107 (bezisterim), an investigational oral small molecule targeting inflammation-driven insulin resistance and neuroinflammation, potentially relevant for Alzheimer's disease (AD), Parkinson's disease (PD), and Long COVID [S1].
• Bezisterim's mechanism involves inhibition of ERK, NFκB, and TNF-α pathways, aiming to reduce neuroinflammation and insulin resistance [S1].
• Phase 2b SUNRISE-PD trial of bezisterim in early-stage PD met its primary pharmacodynamic endpoint showing statistically significant reduction in neuroinflammatory biomarkers and improvements in motor/non-motor clinical composite endpoints [S1].
• Bezisterim was well tolerated with a safety profile comparable to placebo in the SUNRISE-PD trial [S1].
• Previous Phase 2 study of bezisterim with levodopa in PD patients met safety and drug interaction objectives [S1].
• The company is conducting a Phase 2 ADDRESS-LC trial for bezisterim in Long COVID neurological symptoms, with enrollment completed in May 2026 and topline results expected in late summer 2026 [S1].
• BioVie has conducted Phase 2 and Phase 3 trials of bezisterim in AD, with preliminary data suggesting cognitive and biomarker improvements; however, the Phase 3 trial was underpowered due to exclusion of patients from sites with protocol deviations [S1].
• BIV201 (continuous infusion terlipressin) is an investigational drug for liver cirrhosis-related ascites, granted FDA Fast Track and Orphan Drug status, with ongoing Phase 3 protocol finalization [S1].
• BIV201 is a novel liquid formulation designed for outpatient use with patents granted in multiple jurisdictions; terlipressin itself is off-patent [S1].
• Phase 2 study of BIV201 showed a significant reduction in ascites fluid volume compared to standard of care [S1].
• BioVie owns patents covering methods of treating ascites with BIV201 and novel liquid formulations [S1].
• Financial snapshot as of June 30, 2026: cash and equivalents $8.98 million, current assets $13.64 million, current liabilities $3.80 million, net loss $22.07 million, basic and diluted EPS -$3.05, current ratio 3.59, cash ratio 2.37 [S1].
• The company disclosed risks including potential dilution from future equity offerings and milestone-based share issuances related to drug candidates [S2].